Play the New Era of Gene Editing with the ARKG ETF

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) closed June on a strong note. It’s not difficult to explain why. Last weekend, ARKG components Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) revealed encouraging results from an ongoing...